Abstract We evaluated the prognostic and predictive utility of b-tubulin isotype III (TUBB3) tumour gene transcription in early breast cancer patients enrolled in a randomised study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied for assessment of TUBB3, ER, PgR, HER2 and MAPT messenger RNA and immunohistochemistry (IHC) for protein expression in 314 patients enrolled in trial HE10/97, evaluating epirubicin-alkylator adjuvant chemotherapy with or without paclitaxel. High TUBB3 mRNA status was associated with advanced T stage, high histological grade, low mRNA and protein levels of ER, PgR and MAPT, and high levels of HER2 (p \ 0.001). At a median follow-up of 98 months, multivariate analysis showed high TUBB3 mRNA status to have prognostic significance for DFS (HR = 1.83, 95% CI 1.25-2.68, p = 0.002) and OS (HR = 1.71, 95% CI 1.03-2.83, p = 0.038), along with the number of involved axillary nodes, PgR mRNA status and tumour grade. TUBB3 mRNA levels did not predict benefit from inclusion of paclitaxel in adjuvant chemotherapy (test for interaction p = 0.96 for OS, p = 0.46 for DFS). Transcriptional activity of b-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy.
Introduction
Breast adenocarcinoma is the most common malignant neoplasm in females. As many as 60-70% of affected patients present with localised disease and become disease free following surgical resection of the tumour, thus becoming candidates for adjuvant systemic therapy [1] . Several clinicopathological parameters, including tumour size, grade, hormonal receptor status, axillary nodal involvement, patient age and Human Epidermal growth factor Receptor-type 2 (HER2) overexpression are taken into consideration to identify which patients are most likely to benefit from administration of adjuvant cytotoxic chemotherapy [2] . Still, individual patients may be under-or overtreated. Ultimately, we are unable to predict the true binary outcome of recurrence versus no recurrence at the level of the individual, as this simple clinicopathological profile does not capture the rich molecular heterogeneity of the malignancy.
Taxanes are natural products that disrupt the dynamic equilibrium of microtubule polymerisation and cause mitotic arrest and apoptosis of malignant cells. Data from 21 clinical trials of first-generation taxanes that were randomly allocated over 35,000 women with early-stage breast cancer to taxane-based versus taxane-free adjuvant therapies established a modest improvement in patient outcome [3] . This modest benefit was observed irrespective of the type of taxane, schedule of administration, extent of nodal involvement and hormone-receptor status. Taxanes are associated with considerable side effects, often require the use of adjunctive medications and are expensive. Accordingly, controversy persists regarding their role in the adjuvant management of early-stage breast cancer, as a result of our inability to identify the subgroup of patients who would truly benefit. Consequently, the quest for tumoural molecular traits that have the potential to be useful predictive factors for taxane activity is justified.
Microtubules are intrinsically dynamic polymers composed of ab-tubulin heterodimers and constitute essential components of the mitotic spindle and cytoskeleton. Microtubule dynamics control mitosis and cellular motility. Moreover, microtubules serve as scaffolds for signalling molecules and gene transcription regulators, for trafficking of cellular organelles as well as vesicles and for fine-tuning of cell cycle activity [4] . This dynamic network should be seen as polymers of tubulin dimers in flux, as it is in equilibrium with a repertoire of modulating factors, such as the a/b tubulin heterodimer ratio, the b-tubulin isotypes being integrated and the microtubule-associated proteins (MAP) being attached. Altered tumoural expression of b-tubulin isotypes, which constitute the major microtubule proteins, may affect taxane binding and alter microtubule dynamics. At least eight different b-tubulin isotypes (classes I, II, III, IVa, IVb, V, VI and VII) have been identified [5] . In particular, it has been suggested that overexpression of class III b-tubulin (TUBB3) may destabilise microtubules and counteract the effects of taxanes. To date, the clinical data that predict taxane resistance in relation to class III b-tubulin expression in advanced breast cancer are unclear, and this link has yet to be studied in the adjuvant setting [6] . Accordingly, we retrospectively studied the transcription and protein expression of TUBB3 in patients with resected high-risk breast cancer who had been randomised to receive adjuvant chemotherapy in the context of a prospective randomised Hellenic Cooperative Oncology Group (HeCOG) trial. The administration of taxane-based versus taxane-free chemotherapy regimens would allow us to dissect the prognostic versus predictive utility of TUBB3 expression. Moreover, we analysed correlations of TUBB3 expression with clinical, pathological and molecular characteristics of the tumour.
Patients and methods

Clinical trial
The HeCOG prospective trial HE10/97 randomised a total of 595 high-risk (T1-3N1M0 or T3N0M0) breast cancer patients in the period 1997-2000, to receive either four cycles of epirubicin followed by four cycles of intensified cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy (E-CMF) or three cycles of epirubicin followed by three cycles of paclitaxel and three cycles of intensified CMF (E-T-CMF) [7] . Chemotherapy cycles were administered every 2 weeks and patients received granulocyte-colony stimulating factor (GCSF) support. The trial was approved by the Bioethics Committee of the Aristotle University of Thessaloniki, and patients provided written informed consent before enrolment. All participating patients also gave written informed consent for research use of their biologic material.
Molecular and immunohistochemical studies
This was a retrospective translational research study amongst patients who had been enrolled in a prospective clinical trial (A REMARK diagram is provided in Fig. 1) . Accordingly, collection of formalin-fixed paraffin-embedded (FFPE) tumour tissue samples was possible in 317 patients only, because of logistical/organisational barriers. Hematoxylin-eosin sections from all the available FFPE tissue specimens were evaluated histologically by a certified pathologist and recorded for the percentage of tumour cell content. Before RNA isolation, macrodissection of tumour areas was performed for sections with \50% tumour cell content.
Sufficient RNA was isolated from 314 FFPE specimens. In detail, from each FFPE section or macrodissected tissue fragments (10 lm thick), RNA was isolated using a fully automated isolation method for total RNA from FFPE tissue, based on silica-coated magnetic beads (Versant Tissue Preparation Reagents, Siemens Healthcare Diagnostics, Tarrytown, NY) in combination with a liquidhandling robot, as previously described [8] . The method involves DNase I treatment for eliminating DNA contamination in the sample. Quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) was applied for the assessment of the b-tubulin type III (TUBB3) gene, which includes four exons and four introns, using a gene-specific Taq-Man-based assay. The TUBB3 gene is situated at chromosome 16 at the genome locus 16q24.3. Forty cycles of nucleic acid amplification were applied, and the cycle threshold (CT) value of the target gene was identified. CT values were normalised by subtracting the CT value of the housekeeping gene RPL37A from the CT value of the target gene (DCT). RNA results were then reported as 40-DCT values, which would correlate proportionally to the mRNA expression level of the target gene.
Expression of the TUBB3 gene, as well as the reference gene RPL37A, was assessed in triplicate by qRT-PCR using the SuperScript III PLATINUM One-Step Quantitative RT-PCR System with ROX (Invitrogen, Karlsruhe, Germany) in an ABI PRISM 7900HT (Applied Biosystems, Darmstadt, Germany) [9] . [11] . Immunohistochemical staining for TUBB3 and MAPT was homogeneous throughout the TMA sections and was evaluated using a semiquantitative method. In particular, the staining was cytoplasmic and was considered positive if it was of moderate or strong intensity (2? and 3? respectively), as previously described by Pusztai et al. [12] . Cases with absent (0?) or weak (1?) immunostaining were considered negative. The above mentioned criteria were also used for the analysis of the ERCC1 protein. Moderate or strong nuclear-staining intensity was considered as positive, whereas cases with absent or mild immunoexpression were classified as negative.
Statistical methodology
Exploratory analysis was conducted to find a prognostic cut-off amongst the distribution quartiles of TUBB3 mRNA values. The median was chosen as the optimal cutoff in the prognosis of both overall survival (OS) and disease-free survival (DFS). The distribution of the mRNA values of TUBB3 is shown in Fig. 1 . The median for MAPT and the 25th percentile for ER and PgR were used to separate mRNA expression as previously described [13] . Considering mRNA expression of HER2, the 75th percentile (a value close to the natural cut-off of the bimodal distribution) was a predefined threshold to separate low and high expressed tumours.
OS was measured from the date of randomisation until death from any cause. Surviving patients were censored at the date of last contact. DFS was measured from the date of randomisation until recurrence of tumour or secondary neoplasm or death from any cause. Time-to-event distributions were estimated using Kaplan-Meier curves [14] . The non-parametric Mann-Whitney test was performed for comparing continuous variables between two independent groups. To measure the association between the clinicopathological variables and the expression of studied biomolecules, the Fisher's exact test was implemented. Correlations amongst all genes under study were assessed using the Spearman correlation coefficient (Rho). The degree of agreement corrected by chance was estimated using the Kappa coefficient. Univariate Cox regression analyses, adjusted for group, were performed to assess the relationship of markers with OS or DFS. A multivariate Cox regression analysis, including age (\50 vs. C50 years), group of randomisation (E-T-CMF vs. E-CMF), menopausal status (pre vs. post), involved axillary lymph nodes (0-3 vs. C4), histological grade (I-II vs. III-Undifferentiated), size (B2 vs. 2-5 vs.[5 cm), mRNA expression (low vs. high) of ER, PgR, HER2, TUBB3, MAPT and ERCC1 protein expression (negative vs. positive) was conducted. A backward selection procedure with a removal criterion of p [ 0.10 was applied and final tests were conducted at the a = 0.05 level of significance. Results of this study are reported as per the corresponding recommendations for tumour marker prognostic studies [15] . The statistical analysis was conducted using SPSS (SPSS for Windows, version 15.0, SPSS Inc.).
Results
Patient and tumour characteristics
Three hundred and fourteen patients (median age 50) harboured breast carcinomas, most commonly hormonereceptor positive by IHC (68.8% of patients), T2-3 (69.4%) of moderate-to-poor differentiation (49.7%), from which neoplastic FFPE material underwent molecular analysis for gene expression of TUBB3, ER, PgR, HER2 and MAPT ( Fig. 1 ). After modified radical mastectomy (79%) or breast conserving surgery (21%) and nodal dissection, neoplastic metastases in axillary lymph nodes were present in all but six cases, with four or more involved nodes in 75.5% of patients. Slightly more patients were managed with adjuvant E-CMF chemotherapy (N = 170) than E-T-CMF (N = 144). With the exception of high-grade and HER2 IHC protein overexpression, which were more common in the E-T-CMF arm, basic clinicopathological characteristics were well balanced when the 314 analysed patients were stratified by adjuvant chemotherapy arm (Tables 1, 2 ). Following completion of adjuvant chemotherapy, 91.7% of the 314 women received some form of hormonal therapy, mostly tamoxifen (87.2% of patients receiving hormonotherapy). Amongst women with IHC ER-negative tumours who took tamoxifen, a proportion had PgR-unknown or PgR-positive tumours, while some received hormonal therapy despite having both ER and PgR-negative tumours, a practice that has since been abandoned in all HeCOG participating centres. The profiles of protein expression and gene transcription of the studied biomolecules are summarised in Table 2 . Amongst 314 tumours, 64% expressed ER protein, 57% PgR and 17.2% overexpressed HER2. The majority of tumours (71%) expressed ERCC1 protein, while 40% expressed MAPT. Only 36.3% of breast carcinomas stained moderately to strongly for cytoplasmic TUBB3, the definition used for positive cases (Fig. 2a, b) . Regarding RT-PCR studies, gene transcription defined as mRNA levels higher than the defined cut-offs were seen in 75% of tumours for ER and PgR genes, in 25% for HER2 and in 50% of cases for the MAPT and TUBB3 genes. The distribution of TUBB3 mRNA values is shown in Fig. 3 . There were no significant differences in protein expression or gene transcription of the studied biomolecules between treatment arms, with the exception of HER2 protein overexpression, which was seen In contrast, the association of TUBB3 protein expression with adverse clinicopathological variables was less common and considerably weaker. It correlated with HER2 protein overexpression, ERCC1 protein expression and low mRNA status of ER and PgR, as well as high mRNA status of HER2 at p values ranging from 0.01 to 0.047.
Although positive TUBB3 protein expression was associated with higher levels of TUBB3 mRNA (Mann Whitney, p \ 0.001, Fig. 4) , there was only poor agreement between mRNA and protein expression status (Kappa statistic 24.6%, p \ 0.001) ( Table 4 ). In fact, amongst tumours with higher than median TUBB3 mRNA transcription as many as 45.9% exhibited absent or weak (0?/1?) protein staining. Conversely, amongst tumours with lower than median TUBB3 mRNA levels, 29.5% had moderate-to-strong (2?/3?) protein expression. Using the protein expression as reference, overall agreement between the two methods was 62.4%, while positive and negative agreements were 64.0 and 61.2%, respectively. In contrast, neoplastic TUBB3 protein expression did not achieve prognostic significance. Malignant relapses occurred in 28.5%, and deaths in 27.2% of the TUBB3-IHC positive cases versus 33.7% relapsed and 24.3% dead patients with TUBB3-IHC negative tumours. Univariate Cox regression analysis, adjusted for treatment, failed to establish distinct risk of death in patients with TUBB3-IHC high tumours (HR = 1.17, 95% CI: 0.73-1.87, Waldp = 0.52), or risk of relapse (HR = 1.13, 95% CI: 0.76-1.67, Wald-p = 0.56), in comparison to those affected by TUBB3-IHC low breast carcinomas.
Kaplan-Meier survival curves representing the probability of survival and DFS as a function of TUBB3 mRNA status are presented in Fig. 5 (log-rank test for DFS p = 0.001, for OS p = 0.04). The randomisation of patients to a taxane-free versus a taxane-containing chemotherapy regimen enabled us to screen whether TUBB3 gene transcription carried a prognostic (irrespective of treatment) or predictive (identifying response to therapy) utility. However, neither TUBB3 mRNA nor IHC protein expression status was predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for either DFS or OS (DFS and OS tests for interaction, Wald-p = 0.46 and p = 0.96 for TUBB3 mRNA, p = 0.95 and p = 0.75 for TUBB3 IHC, respectively). Since data on TUBB3 mRNA levels are continuous, we examined whether increasing tumour mRNA levels had a trend for increasing patient benefit from taxane-containing adjuvant chemotherapy. There was no interaction between mRNA levels of TUBB3 and treatment arm (p = 0.27 for OS and p = 0.15 for DFS). By restricting analysis to patients who received taxanes (E-T-CMF), we observed that increasing transcription of the TUBB3 gene (increasing mRNA levels as a continuous variable) remained non-predictive for benefit from adjuvant treatment with paclitaxel (DFS HR = 1.11 and OS HR = 1.14, Wald-p = 0.14 and p = 0.15, respectively). The impact of paclitaxel on OS and DFS in TUBB3 mRNA-low and high patients are shown in Fig. 6a, b , respectively. Since in the clinical paper, a survival benefit from the addition of paclitaxel was observed in patients harbouring ER IHC-negative tumours and ER status was inversely correlated to TUBB3 gene transcription, we investigated whether TUBB3 gene transcription was able to identify the subgroup of patients with ER IHC negative tumours who might benefit from taxanes. This analysis amongst ER IHC-negative patients is presented in Fig. 7a , b, respectively, and does not show any impact of paclitaxel on either DFS or OS (log-rank, p [ 0.05 in all cases).
In keeping with data published by our group on MAPT mRNA levels, IHC MAPT expression exhibited a trend for statistical significance as a favourable prognostic factor for OS (HR = 0.63, 95% CI: 0.39-1.02, Wald-p = 0.065) and DFS (HR = 0.66, 95% CI: 0.44-1.00, Wald-p = 0.05). Although, there was a non-significant trend for the interaction of MAPT protein expression and treatment group (p = 0.08 for both OS and DFS), there was a favourable prognostic significance for MAPT IHC protein staining when restricting in patients treated in the E-CMF arm (HR for OS = 0.42 with Wald-p = 0.014 and HR for DFS = 0.45 with Wald-p = 0.009).
Multivariate analysis for independent prognosticators
Multivariate Cox regression analysis (Table 5) 
Discussion
Both a-and b-tubulins are encoded by a 9-and 8-member multigene family, respectively, that produces conserved gene products in which the sequences are divergent only in their last carboxy-terminal 10-15 aminoacids. This carboxy-terminal sequence has been used to define b-tubulin gene products to seven distinct classes or isotypes [16] [17] [18] . Class I and II b-tubulins are the most abundant isotypes, whereas the class III b-tubulin (TUBB3) was initially thought to be restricted to neuronal and testicular tissues. The TUBB3 gene is situated at chromosome 16 at the genome locus 16q24.3. Recently, however, TUBB3 expression has been observed in the mitochondria and cytoplasm of other tissues [19] . In vitro experiments and retrospective in vivo data implicated TUBB3 as a clinical marker of drug resistance to taxanes and vinca alkaloids [6] . These drugs respectively stabilise and depolymerise microtubules at high concentrations, though at concentrations 10-100 times lower, such as the ones achieved in the clinical setting, they kinetically disrupt microtubule dynamics without altering microtubule polymer mass [20] . This results in blocking transition from metaphase to anaphase and inducing apoptotic cell death. High levels of TUBB3 were associated with taxane resistance in lung, ovarian, breast, and pancreatic cancer cell lines. TUBB3 has been hypothesised to alter drug binding to tubulin dimers and to reduce the polymerisation rate of microtubules, thus overcoming polymerisation induced by taxanes, or to create ab III microtubule dimers with different intrinsic dynamic properties that render them less sensitive to antitubulin agents [21, 22] . Molecular modelling experiments showed that Ser277, the aminoacid in the M-loop of microtubules that interacts with taxanes, is replaced by an arginine residue in the class III b-tubulin that does not bind the drug and consequently, does not result in stabilisation of lateral microtubules [23] . Several retrospective clinical series of rather small size confirmed the cell line data and correlated protein or mRNA expression of TUBB3 to resistance to taxanes [24] . Still, these series could not discern the prognostic (patient outcome irrespective of therapy) versus predictive (probability of benefit from taxane-based therapy) significance of this biomolecule.
Our retrospective analysis of 314 patients with high-risk resected breast cancer used quantitative mRNA transcription levels of TUBB3. We showed for the first time in the adjuvant setting that TUBB3 RNA expression in breast cancer tissues is significantly correlated to adverse clinicopathological characteristics (advanced T stage, anaplasia, hormone receptor negativity, HER2 overexpression, etc.) and inferior patient outcome. Moreover, multivariate analysis revealed that high TUBB3 mRNA transcription retained independent prognostic significance for both OS and DFS. Finally, the randomisation of patients to a taxanecontaining and a taxane-free chemotherapy arm enabled us to show that TUBB3 gene transcription is prognostic for adverse outcome but not predictive for resistance to taxanes. Taking into consideration the high p values for interaction of TUBB3 status with treatment arm and the moderately large sample size, we can rather confidently a TUBB3 mRNA-low Evidence from other investigators seem to confirm our findings and refute the taxane-resistant phenotype hypothesis for TUBB3. In the JBR.10 trial, 482 patients with resected non-small cell lung cancer were randomised to observation versus adjuvant cisplatin/vinorelbine chemotherapy [25] . In 265 patients examined, immunohistochemical TUBB3 protein expression was prognostic for poorer recurrence-free and OS in the observation, but not in the chemotherapy arm. Cox regression analysis failed to establish a significant interaction between TUBB3 IHC expression and chemotherapy in predicting outcome. Very recently, Dumontet et al. analysed 1350 patients with resected node-positive breast cancer who had been randomised to TAC (docetaxel, adriamycin, cyclophosphamide, etc.) versus FAC adjuvant chemotherapy by studying the immunohistochemical protein expression of several biomolecules [26] . In multivariate analysis, high TUBB3 protein expression was significantly associated with poorer OS but lacked predictive utility for docetaxel efficacy, as the correlation with outcome was observed in both TAC and FAC arms and interaction testing revealed no differences within treatment subgroups. In our study, we failed to show any TUBB3 predictive significance for taxane benefit even when we restricted our analysis to two patient subgroups: 1) In those patients who received the taxanecontaining therapy (E-T-CMF), there was no association of increasing TUBB3 mRNA levels with outcome, rather convincingly establishing the lack of a dose-response relation between gene transcription and taxane effect. 2) Since in the HE10/97 trial a benefit from taxane was seen only in patients with ER IHC-negative tumours, we analysed and failed to find any predictive significance of TUBB3 mRNA status for taxane efficacy in the ER IHCnegative subgroup.
The adverse prognostic, but not predictive significance of TUBB3 mRNA may not seem paradoxical in view of emerging in vitro data: the TUBB3 gene is located at 16q24.3 and contains a promoter region, an enhancer sequence and an E-box-binding site for transcription factors that all drive its transcription. Hypoxia-dependent transcription factors, such as Stimulating Protein-1, Wilms tumour suppressor, p53, and NFkB induce gene expression, in keeping with the observation that TUBB3 is more expressed in hypoxic tumours (breast, ovarian cancer) than in normal mammary and ovarian biopsies [27, 28] . Gan et al. have recently shown that TUBB3 is overexpressed not only in taxane-resistant but also in cisplatin-refractory cancer cell lines [29] . TUBB3 indeed interacts with a Fig. 7 OS (left) and DFS (right) for E-T-CMF and E-CMF in TUBB3 mRNA-low and high patients restricted to ER IHC-negative tumours plethora of cellular proteins, such as HSP70, FMO4 and Pyruvate Kinase M1. A functional analysis of the network of proteins associated to TUBB3 shows that many of them are involved in oxidative stress, glucose deprivation response and cell cycle control [19] . Accordingly, TUBB3 seems to be integrated in a survival pathway, which is initiated by hypoxia and effects adaptation of cancer cells to a microenvironment with low oxygen and poor nutrient supply. Increased TUBB3 gene transcription could therefore be a marker of aberrant activation of this «hypoxia lethal phenotype», resulting in cancer proliferation, metastatic dissemination and poor patient outcome. In addition to increased transcription, other mechanisms such as TUBB3 gene amplification, epigenetic regulation or decreased expression of repressing RNAs, such as microRNAs, might contribute to relatively high TUBB3 mRNA expression. Amplification of the TUBB3 gene seems, in fact, unlikely and has not been reported in breast cancer; the chromosomal region 16q24.3, as well as genes located centromerically or telomerically to TUBB3 have repeatedly been reported as deleted in breast cancer [30] [31] [32] . In regard to the latter two options, TUBB3 gene transcription seems to be induced by hypoxia in cisplatin-sensitive ovarian cancer cells lacking methylation in the 3'-enhancer region of this gene, while the miR-200 family that, amongst other targets, represses TUBB3 mRNA is downregulated in human cancer cells (Mongroo and Rustgi 2010) [28, 33] . Whether these mechanisms apply to breast cancer tissues warrants further investigation.
The correlation of TUBB3 mRNA levels with protein expression was poor in our study, with a Kappa statistic of only 0.24. Moreover, in contrast to protein, mRNA expression was associated strongly with adverse clinicopathological factors and retained independent prognostic significance for outcome. Amongst hypotheses that could interpret the finding, we could cite mRNA failing to translate to protein (alternate splicing, aberrant polyadenylation, microRNA-mediated or other form of translational silencing), protein degradation in the tumour block by inadequate fixation, problematic antigen retrieval, protein staining underestimation in old archival material, or finally, RNA amplification of normal tissue along with the tumour [34] [35] [36] . Conversely, protein staining in the face of low level gene transcription could be due to the difficulty in capturing short-lived, sensitive to degradation mRNA from FFPE tumour blocks, the different fixation and turnover times of ribonucleic acids in relation to proteins, as well as accumulation of protein due to aberrant catabolism [37, 38] . In any case, TUBB3 mRNA as a continuous, objectively measured variable, was shown to possess correlative and prognostic characteristics not present when evaluating expression of the corresponding protein.
In a report previously published by our group, we have shown that high-level Tau gene (MAPT) transcription has prognostic significance for favourable patient outcome, though no predictive utility for taxane benefit [13] . Our findings were confirmed by the demonstration of prognostic, but not predictive utility for Tau protein expression amongst breast cancer patients receiving taxane-based adjuvant chemotherapy in the NSABP-B28 (n = 1942) and the BCIRG001 (n = 1350) randomised trials [26, 38] . Still other investigators have reported association between low MAPT mRNA or IHC levels with response to taxanes and resistance to tamoxifen [39, 40] . In our previous report, we had speculated that, since all patients who had received adjuvant taxane therapy were also managed with hormonotherapy, in those with low MAPT mRNA levels the positive predictive significance for taxane benefit could have been 'cancelled' by the predictive utility for tamoxifen resistance. In this study, MAPT protein expression had strong favourable prognostic significance only in patients receiving E-CMF, but not in those receiving a taxane. It is tempting to speculate that in the E-T-CMF patients, the favourable prognosis afforded by MAPT protein overexpression was diluted by the lack of taxane efficacy. This observation could serve as additional preliminary evidence that high MAPT gene or protein expression serve as both markers of favourable prognosis and markers of resistance to taxanes. To conclude, our work has established a prognostic significance of the transcription of two gene products related to microtubules, b-tubulin isotype III and MAPT. These biomolecules could serve as useful prognosticators and stratification factors in future trials. Still, their function and relation to other biomolecules should be further investigated, while their prognostic and potentially predictive value remains to be validated. HeCOG plans to validate these findings in over 900 breast cancer blocks from a subsequent adjuvant chemotherapy study (He 10/00).
